PIK3CD and B-cell chronic lymphocytic leukemia: Genomic analysis revealed an amplification of PIK3CA in 3.5% of CLL patients, which is perhaps surprising when all the significant pharmaceutical effort to inhibit the PI3K pathway in this malignancy is considered (37).